Results 111 to 120 of about 1,264,680 (377)

Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]

open access: yes, 2017
AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA   +6 more
core   +1 more source

Fluorescent Nanodiamonds Based Theranostic Platform for pH‐Sensitive Drug Delivery and Quantum Sensing

open access: yesAdvanced Functional Materials, EarlyView.
A multifunctional nanodiamond platform enables pH‐triggered Diazoxide (DZX) delivery and quantum sensing of subcellular radical dynamics in triple‐negative breast cancer cells. Diamond relaxometry revealed reduced lysosomal radicals during DZX‐induced mitochondrial radical elevation, providing insights into redox modulation and organelle‐ resolved ...
Kaiqui Wu   +8 more
wiley   +1 more source

The role of central corneal thickness in the diagnosis of glaucoma

open access: yesIndian Journal of Ophthalmology, 2000
Purpose: To determine the effect of central corneal thickness (CCT) on applanation tonometry and any resultant misclassification of normals as ocular hypertension.
Thomas Ravi   +2 more
doaj  

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension

open access: yesClinical and experimental optometry, 2019
Latanoprostene bunod (LBN) ophthalmic solution 0.024% is a novel, once‐daily, nitric oxide‐donating prostaglandin analogue for the lowering of intraocular pressure (IOP) in patients with open‐angle glaucoma and ocular hypertension.
M. Fingeret, I. Gaddie, M. Bloomenstein
semanticscholar   +1 more source

Blood pressure and indices of glomerular filtration area in hypertensive and normotensive Prague rats [PDF]

open access: yes, 2000
The involvement of the kidney in the pathogenesis of hypertension has long been recognised, although the specific renal mechanisms underlying this phenomenon are still unknown.
Davis, J. M., Hellmann, H., Thurau, K.
core   +1 more source

Bioprinting Organs—Science or Fiction?—A Review From Students to Students

open access: yesAdvanced Healthcare Materials, EarlyView.
Bioprinting artificial organs has the potential to revolutionize the medical field. This is a comprehensive review of the bioprinting workflow delving into the latest advancements in bioinks, materials and bioprinting techniques, exploring the critical stages of tissue maturation and functionality.
Nicoletta Murenu   +18 more
wiley   +1 more source

Therapeutic problems in ocular hypertension

open access: yesIndian Journal of Ophthalmology, 1983
Sood N, Grover A, Agarwal H
doaj   +2 more sources

Corneal Biomechanics for Ocular Hypertension, Primary Open-Angle Glaucoma, and Amyloidotic Glaucoma: A Comparative Study by Corvis ST

open access: yesClinical Ophthalmology, 2022
Nisa Silva,1 André Ferreira,1,2 Pedro Manuel Baptista,1 Ana Figueiredo,1 Rita Reis,1 Isabel Sampaio,1 João Beirão,1,3 Riccardo Vinciguerra,4,5 Pedro Menéres,1,3 Maria João Menéres1,3 1Ophthalmology Department, Centro Hospitalar Universitário do Porto ...
Silva N   +9 more
doaj  

Endogenous hypercortisolism inducing reversible ocular hypertension

open access: yesAmerican Journal of Ophthalmology Case Reports, 2019
Purpose: To describe the clinical findings of two patients with reversible ocular hypertension secondary to endogenous hypercortisolism. Design: Retrospective, observational case series.
Shane Griffin   +5 more
doaj   +1 more source

Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs. [PDF]

open access: yes, 2019
There is a limit beyond which increasing either the concentration of a prostaglandin analog (PGA) or its dosing frequency fails to produce increases in ocular hypotensive efficacy with topical dosing.
Alm   +36 more
core   +2 more sources

Home - About - Disclaimer - Privacy